We designed the EURAMOS-1 trial to investigate whether intensified .. and a normal creatinine concentration for their age as per protocol. EURAMOS-1, an international randomised study for osteosarcoma: Results from Pre-operative chemotherapy was completed according to protocol in 94%. The EURAMOS 1 trial is a multimodal therapy of osteosacoma with precluding treatment with protocol chemotherapy (for example HIV.
|Published (Last):||11 February 2007|
|PDF File Size:||1.74 Mb|
|ePub File Size:||17.46 Mb|
|Price:||Free* [*Free Regsitration Required]|
Kager25 T. Nagarajan34 R.
Page Not Found
Schwarz37 L. Uniform response of metastases to high dose ifosfamide. The feasibility of delivering intensive chemotherapy for a rare cancer in multiple centres within a Good Clinical Practice framework is amply demonstrated here. Spastic diplegia as a complication of interferon alfa-2a treatment of hemangiomas of infancy.
Therefore, this study addressed separate treatment questions based on histological response.
There was some variability in eursmos randomised between groups: New models of collaboration are required to successfully conduct trials to improve outcomes of patients with rare cancers; EURAMOS-1 demonstrates achievability.
Pediatric and Adolescent Osteosarcoma Series: Further investigation of this important area is needed [ 27 ]. CitePeer Related Articles http: Perceptions of participants and professionals in bone sarcoma clinical trials: The study was developed through a commitment to collaboration between four well-established study groups.
The results were further improved during the next decade, but since then, no clinically significant advances have been made in survival, although more patients access combination chemotherapy within and outside trials. International collaboration is feasible in trials for rare conditions: Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: With patients with resectable osteosarcoma furamos, it doubled the size of the previous largest RCT in this population and accrual was completed in around 6 years.
While the link between increased toxicity and improved survival from osteosarcoma remains to be unravelled [ 26 ], future approaches must look to reduce this burden as well as improve efficacy. Hall22 K.
Median time from surgery to starting post-operative chemotherapy for randomised patients was 18 days IQR 14; Consent was obtained according to national regulations. EURAMOS-1 is an academic clinical trial funded through multiple national and international government agencies and cancer charities see http: This article has been cited by other articles in PMC. Randomization must be performed within 35 days from date of definitive surgery.
English translations are euraamos in development. There were three 0. However, the agents chosen highlight the paucity of new or investigational products appropriate to include in phase III trials. P therapeutic intensification in non-metastatic osteosarcoma: Survival from high-grade localised extremity osteosarcoma: Gosheger20 R. CTCAE grade 3—4 toxicity was common: Gene Ontology GO Terms.
Page Not Found | MRC Clinical Trials Unit at UCL
Click here to view. The treatment-related death rate of 0. Information collected on reasons for non-randomisation has been relatively non-informative but anecdotally, young people expressed a reluctance to risk allocation to experimental treatments that were substantially longer than the standard MAP schedule.
Hook6 M. First results of the Good Response randomisation have been presented orally [ 28 ], with a clear demonstration that large-scale practice-changing randomised, controlled trials can be undertaken in rare cancers by extending the traditional boundaries of collaboration.